RKM3 Antibody

What is RKM3/RBM3 antibody and what are its primary research applications?

RBM3 antibody is a research tool designed to detect and study the cold-inducible RNA-binding protein RBM3, which plays crucial roles in mRNA translation, stress response, and cellular adaptation to hypothermia. The antibody is widely applied in neurodegeneration studies, tumor upregulation analysis, and cold stress adaptation research.

In research settings, RBM3 antibodies have been instrumental in several key areas:

• Investigating structural plasticity mechanisms, particularly in relation to synaptic preservation under hypothermic conditions in mouse models

• Studying neurogenesis processes where RBM3 regulates Yap mRNA stability to promote neural stem cell proliferation during cold stress

• Examining oncogenic potential, as RBM3 overexpression correlates with tumor progression in hepatocellular carcinoma and lung adenocarcinoma

• Exploring therapeutic targets, where RBM3 has been identified as a proto-oncogene in HER2+ cancers

What are the common validation methods for RKM3/RBM3 antibody specificity?

Validation of RBM3 antibody specificity typically involves multiple complementary approaches:

• Western blotting (WB): Used at dilutions ranging from 1:5,000 to 1:50,000 to confirm specific binding to the target protein of expected molecular weight

• Immunohistochemistry (IHC): Applied at dilutions of 1:50 to 1:500 to visualize protein expression in tissue sections

• Immunofluorescence/Immunocytochemistry (IF/ICC): Utilized at dilutions of 1:50 to 1:500 for cellular localization studies

Enhanced validation protocols include:

• siRNA knockdown studies to confirm antibody specificity

• GFP colocalization experiments to verify proper cellular targeting

• Comparison with RNA expression data in repositories like the Human Protein Atlas to assess consistency between protein detection and transcript levels

How does RKM3/RSK3 antibody function in cellular signaling research?

RSK3 antibody (targeting ribosomal protein S6 kinase alpha-2/RPS6KA2) is utilized to study serine/threonine-protein kinase activity in the ERK signaling pathway. This antibody facilitates research on how RSK3 mediates mitogenic and stress-induced activation of transcription factors, regulates translation, and influences cellular proliferation, survival, and differentiation .

The antibody is particularly valuable for investigating the potential tumor suppressor role of RSK3 in epithelial ovarian cancer cells, allowing researchers to elucidate mechanisms by which this protein may inhibit tumor progression .

What are the optimal experimental conditions for RKM3/RBM3 antibody application in Western blotting?

For optimal Western blotting with RBM3 antibody:

• Sample preparation:

  • Use whole cell lysates (30 μg protein loading recommended)

  • For best results, prepare samples from tissues or cell types known to express the target (e.g., HepG2 cells for hepatocellular studies)

• Electrophoresis conditions:

  • Use 7.5% SDS-PAGE gels for optimal protein separation

  • Include appropriate molecular weight markers (predicted band size for RBM3 is variable depending on isoform)

• Transfer and detection:

  • Recommended antibody dilution: 1:5,000 to 1:50,000 (optimize for your specific application)

  • Blocking: 5% non-fat milk in TBST or BSA-based blocking buffer

  • Secondary antibody: HRP-conjugated anti-rabbit IgG at 1:5,000 to 1:10,000

• Controls:

  • Positive control: Tissue/cells known to express the target protein

  • Negative control: Samples from knockout models or siRNA-treated cells

  • Loading control: Probing for housekeeping proteins such as GAPDH or β-actin

Citations in literature indicate successful application in 31+ Western blotting studies, suggesting robustness of the method when properly optimized.

How can researchers effectively design experiments to study RKM3/RBM3's role in cold stress adaptation?

An effective experimental design for studying RBM3's role in cold stress adaptation should incorporate:

• Model system selection:

  • In vitro: Neuronal cell lines, primary neurons, or hepatocytes are recommended

  • In vivo: Mouse models with conditional RBM3 expression/knockout

• Temperature paradigm:

  • Moderate hypothermia (32-33°C) for cell culture studies

  • Controlled cooling protocols for in vivo studies (e.g., 4-6 hours at 5°C followed by rewarming)

• Key endpoints and measurements:

  • Protein synthesis rate (using puromycin incorporation assays)

  • Polysome profiling to assess global translation

  • mRNA stability assessments using actinomycin D chase experiments

  • Synaptic plasticity markers (PSD95, synaptophysin) for neuronal studies

• Validation approaches:

  • RBM3 overexpression and knockdown studies to establish causality

  • Rescue experiments to confirm specificity

  • Pharmacological manipulation of downstream pathways

What methodological approaches should be used to investigate potential cross-reactivity of RKM3 antibodies?

To rigorously investigate potential cross-reactivity of RKM3 antibodies, researchers should implement:

• Epitope analysis:

  • Perform in silico analysis to identify proteins with similar epitope sequences

  • Use peptide arrays to map the exact binding epitope of the antibody

  • Compare sequence homology between target and related proteins

• Experimental validation:

  • Test antibody against recombinant proteins of the target and closely related family members

  • Perform immunoprecipitation followed by mass spectrometry to identify all proteins captured

  • Use knockout/knockdown systems to confirm specificity

  • Test multiple antibodies targeting different epitopes of the same protein

• Cross-platform validation:

  • Compare antibody detection with mRNA expression data

  • Use orthogonal detection methods (e.g., CRISPR-tagged endogenous proteins)

  • Implement immunohistochemistry with in situ hybridization on the same samples

Researchers should note that the phage display experiments described in the literature provide a framework for assessing antibody specificity against multiple ligands simultaneously, which can be adapted to test for cross-reactivity .

How can researchers utilize RKM3/RBM3 antibodies in studying neurodegenerative disease mechanisms?

Utilizing RBM3 antibodies in neurodegenerative disease research requires sophisticated methodological approaches:

• Temporal expression profiling:

  • Map RBM3 expression across disease progression using immunohistochemistry

  • Correlate with markers of neurodegeneration (e.g., Tau, amyloid-β, α-synuclein)

  • Implement dual immunofluorescence to assess colocalization with stress granules

• Functional intervention studies:

  • Apply cooling protocols in disease models to induce RBM3 expression

  • Use viral vectors for RBM3 overexpression in specific brain regions

  • Employ CRISPR/Cas9 to create conditional knockouts in adult neurons

  • Assess impact on disease progression through behavioral and histopathological readouts

• Molecular mechanism investigation:

  • Perform RBM3 immunoprecipitation followed by RNA sequencing to identify bound transcripts

  • Use CLIP-seq to map RNA binding sites in vivo

  • Analyze post-translational modifications of RBM3 using phospho-specific antibodies

  • Assess RBM3's impact on protein aggregation using biochemical fractionation

Studies have demonstrated that RBM3 upregulation reduces neuronal loss in prion disease models, suggesting its potential as a therapeutic target. Researchers should design experiments that can distinguish between RBM3's direct effects on protein misfolding versus its effects on global protein synthesis and quality control mechanisms.

What are the cutting-edge techniques for enhancing specificity in RKM3 antibody development?

Cutting-edge techniques to enhance RKM3 antibody specificity include:

• Rational epitope design:

  • Utilize structural biology data to identify unique epitopes

  • Implement computational prediction of immunogenic regions with minimal homology to other proteins

  • Design conformational epitopes that capture protein-specific tertiary structures

• Advanced selection methodologies:

  • Implement negative selection strategies against closely related proteins

  • Utilize phage display with customized selection conditions that enhance specificity

  • Apply deep mutational scanning to identify optimal binding variants

  • Employ machine learning algorithms to predict cross-reactivity

• Post-selection engineering:

  • Apply targeted mutagenesis to CDR regions to enhance specificity

  • Implement affinity maturation under stringent conditions

  • Use yeast display for fine-tuning binding properties

  • Design bi-epitopic antibodies that require simultaneous binding to two distinct epitopes

The phage display experiments described in the research literature demonstrate how antibody libraries can be selected against various combinations of ligands to develop highly specific binders. Models derived from such experiments can predict and design novel antibody sequences with predefined binding profiles—either cross-specific (interacting with several distinct ligands) or highly specific (interacting with only one target while excluding others) .

How do RKM3/RSK3 antibodies contribute to understanding tumor suppressor mechanisms in cancer research?

RSK3 antibodies enable sophisticated investigations into tumor suppressor mechanisms through:

• Expression correlation studies:

  • Analyze RSK3 expression across tumor types and correlate with clinical outcomes

  • Perform tissue microarray analysis to map expression patterns in large patient cohorts

  • Use multiplexed immunofluorescence to assess co-expression with other pathway components

• Functional characterization:

  • Implement CRISPR/Cas9-mediated gene editing to create isogenic cell lines

  • Perform phosphoproteomic analysis following RSK3 modulation

  • Map RSK3-dependent transcriptional networks using ChIP-seq of downstream factors

  • Analyze cell cycle progression, apoptosis resistance, and migration phenotypes

• Pathway integration analysis:

  • Study RSK3's position in the ERK signaling cascade using phospho-specific antibodies

  • Identify RSK3-specific substrates through kinase assays and mass spectrometry

  • Investigate compensatory mechanisms in RSK3-deficient models

  • Examine interaction with tumor microenvironment factors

RSK3 (encoded by RPS6KA2) has been identified as a potential tumor suppressor in epithelial ovarian cancer. Researchers can employ RSK3 antibodies to investigate how this kinase mediates its suppressive effects through regulating transcription factors, translation, and cellular processes including proliferation, survival, and differentiation .

How should researchers address inconsistent results when using RKM3 antibodies across different experimental systems?

When confronting inconsistent results with RKM3 antibodies across experimental systems:

• Systematic validation:

  • Test multiple antibody lots and sources

  • Validate antibody performance in each experimental system independently

  • Implement titration experiments to determine optimal concentration for each application

  • Assess epitope accessibility in different sample preparation methods

• Context-dependent expression analysis:

  • Verify target protein expression levels in each model system (using orthogonal methods like qPCR)

  • Consider post-translational modifications that might affect epitope recognition

  • Evaluate the presence of splice variants or isoforms specific to certain tissues or conditions

  • Examine protein complex formation that might mask epitopes

• Protocol optimization:

  • Adjust fixation methods for immunohistochemistry/immunofluorescence

  • Modify extraction buffers to ensure complete protein solubilization

  • Optimize blocking agents to reduce background

  • Implement epitope retrieval methods appropriate for each tissue type

• Quantitative assessment:

  • Implement standardized positive controls across experiments

  • Use recombinant protein standards for calibration

  • Apply digital image analysis with consistent thresholding

  • Consider absolute quantification methods where appropriate

According to the research data, antibody validation shows variability in results, necessitating third-party verification to ensure reliability. Recombinant antibodies generally show higher specificity compared to polyclonal counterparts.

What are the best approaches for interpreting RKM3/RBM3 antibody data in the context of conflicting functional studies?

When interpreting RBM3 antibody data amidst conflicting functional studies:

• Context-specific analysis:

  • Stratify data by experimental conditions (temperature, cell type, disease state)

  • Consider temporal dynamics of RBM3 expression and function

  • Analyze potential bidirectional effects depending on cellular context

  • Evaluate dose-dependent responses rather than binary outcomes

• Methodological reconciliation:

  • Catalog methodological differences between conflicting studies

  • Assess antibody epitopes used in different studies (N-terminal vs. C-terminal)

  • Evaluate knockout/knockdown efficiency and specificity

  • Consider off-target effects of genetic manipulation tools

• Pathway integration:

  • Map RBM3 function within larger signaling networks

  • Identify conditional dependencies that might explain context-specific effects

  • Consider compensatory mechanisms that might mask phenotypes

  • Integrate multi-omics data to build comprehensive functional models

• Resolution strategies:

  • Design decisive experiments addressing specific contradictions

  • Implement rescue experiments with mutant variants to pinpoint functional domains

  • Use multiple orthogonal approaches to validate key findings

  • Consider mathematical modeling to reconcile apparently conflicting data

The literature indicates that RBM3 exhibits seemingly contradictory functions in different contexts—acting as both a neuroprotective factor in cold stress and a potential oncogene in certain cancers. Careful consideration of cellular context and experimental conditions is essential for correctly interpreting these functional differences.

How can researchers distinguish between true RKM3/RBM3 signal and artifacts in immunohistochemistry applications?

To distinguish between true RBM3 signal and artifacts in immunohistochemistry:

• Comprehensive controls implementation:

  • Include no-primary-antibody controls to assess secondary antibody specificity

  • Use isotype controls matched to primary antibody

  • Implement known positive and negative tissue controls

  • Include tissue from knockout models when available

  • Apply peptide competition assays to confirm specificity

• Signal validation approaches:

  • Compare staining patterns across multiple antibodies targeting different epitopes

  • Correlate immunostaining with in situ hybridization for mRNA detection

  • Implement dual immunofluorescence with markers of expected subcellular localization

  • Validate against GFP-tagged protein expression patterns

• Quantitative assessment:

  • Apply digital pathology tools with standardized scoring algorithms

  • Implement blinded evaluation by multiple observers

  • Use automated image analysis with machine learning algorithms for unbiased quantification

  • Establish signal-to-noise ratio thresholds for positive determination

• Technical optimizations:

  • Test multiple antigen retrieval methods (heat vs. enzymatic)

  • Evaluate different fixation protocols (duration, fixative composition)

  • Optimize blocking solutions to reduce non-specific binding

  • Implement tyramide signal amplification for low-abundance targets

According to published research, antibody staining shows moderate alignment with RNA expression data in repositories like the Human Protein Atlas, suggesting that corroborating IHC findings with orthogonal techniques is essential for reliable interpretation.

How is artificial intelligence being integrated into RKM3 antibody development and application?

Artificial intelligence is transforming RKM3 antibody development and application through:

• Epitope prediction and optimization:

  • Deep learning algorithms predict immunogenic epitopes with minimal cross-reactivity

  • AI models analyze protein structures to identify accessible and stable epitopes

  • Machine learning approaches optimize antibody sequences for affinity and specificity

  • Neural networks predict post-translational modifications that might affect epitope recognition

• Experimental design enhancement:

  • AI systems design optimal selection strategies for phage display

  • Algorithms identify minimal antibody panels needed for comprehensive target coverage

  • Predictive models optimize experimental conditions for highest signal-to-noise ratio

  • Computer vision systems automate and standardize antibody validation protocols

• Data interpretation revolution:

  • Deep learning algorithms analyze immunohistochemistry images with superhuman precision

  • AI systems integrate antibody-generated data across multiple experiments and platforms

  • Machine learning models identify patterns in antibody binding data invisible to human researchers

  • Predictive analytics anticipate antibody performance in new applications or tissues

The research literature describes AI-assisted antibody discovery as an emerging approach, where computational models are trained on experimental selection data to optimize over antibody sequences and predict binding profiles. This allows for the design of novel antibodies with custom specificity profiles, either cross-specific (interacting with several ligands) or highly specific (interacting with a single target while excluding others) .

What are the emerging applications of RKM3/RBM3 antibodies in therapeutic development research?

Emerging therapeutic applications of RBM3 antibodies in research include:

• Neuroprotection strategies:

  • Targeting cold-induced neuroprotection pathways that upregulate RBM3

  • Developing small molecules that mimic RBM3's protective effects

  • Identifying critical RNA targets of RBM3 for therapeutic intervention

  • Researching RBM3-mediated synaptic preservation mechanisms applicable to neurodegenerative diseases

• Cancer therapy approaches:

  • Stratifying tumors based on RBM3 expression for personalized treatment

  • Investigating RBM3 inhibition in cancer types where it functions as an oncogene

  • Exploring synthetic lethality approaches in RBM3-dependent cancers

  • Developing RBM3-targeted antibody-drug conjugates for specific cancer subtypes

• Stress response modulation:

  • Exploring RBM3's role in cellular adaptation to various stressors

  • Investigating translational reprogramming mechanisms for broad therapeutic applications

  • Developing biomarkers for stress resilience based on RBM3 dynamics

  • Engineering cell therapies with enhanced RBM3 expression for improved survival

• Tissue preservation applications:

  • Researching RBM3's potential in organ preservation for transplantation

  • Exploring applications in trauma and ischemia-reperfusion injury

  • Developing ex vivo perfusion systems incorporating RBM3 modulators

  • Investigating RBM3's role in hypothermic protection during surgical procedures

RBM3 has been identified as both a therapeutic target in HER2+ cancers (as a proto-oncogene) and as a potential neuroprotective agent in neurodegenerative diseases, highlighting the context-dependent nature of its functions and the importance of careful target validation in therapeutic development.

How do advanced antibody engineering techniques impact the development of next-generation RKM3 research tools?

Advanced antibody engineering techniques are revolutionizing next-generation RKM3 research tools through:

• Format diversification:

  • Development of single-domain antibodies for accessing restricted epitopes

  • Engineering bispecific antibodies for simultaneous targeting of RKM3 and pathway components

  • Creating intrabodies for live-cell imaging and manipulation of endogenous protein

  • Designing antibody fragments optimized for specific applications (Fab, scFv, nanobodies)

• Functional enhancement:

  • Site-specific conjugation techniques for precise labeling

  • pH-sensitive antibodies for conditional binding in specific cellular compartments

  • Engineering extended half-life variants for long-term imaging studies

  • Developing conditionally active antibodies responsive to experimental triggers

• Production advancement:

  • Cell-free synthesis systems for rapid antibody generation

  • Engineering glycosylation patterns for enhanced stability and reduced immunogenicity

  • Implementing high-throughput production platforms for antibody variant libraries

  • Developing recombinant expression systems with precise quality control

• Application expansion:

  • Creating photoswitchable antibodies for super-resolution microscopy

  • Developing antibody-enzyme fusions for proximity-based labeling of interaction partners

  • Engineering split-antibody complementation systems for protein-protein interaction studies

  • Integrating antibodies with CRISPR-Cas systems for targeted protein manipulation

The literature describes how phage display technology, transgenic mice producing fully human antibodies, single B-cell antibody technology, and AI-assisted discovery are transforming antibody development. These approaches are being combined to create increasingly sophisticated research tools with unprecedented specificity and functionality .